Angela Justice - 31 Aug 2021 Form 4 Insider Report for TCR2 THERAPEUTICS INC.

Role: Chief People Officer
Signature: /s/ Margaret Siegel as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 31 Aug 2021
Net transactions value: +$5,405
Form type: 4
Filing time: 10 Dec 2021, 15:32:12 UTC
Next filing: 18 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCRR	Common Stock	Award	$5,405	+379	+5.4%	$14.26^*	7,457	31 Aug 2021	Direct	F1, F2
holding	TCRR	Common Stock						7,078	31 Aug 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TCRR	Stock Option (Right to Buy)	Award	$0	+76,500		$0.000000	76,500	09 Dec 2021	Common Stock	76,500	$5.21	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of March 1, 2021 through August 31, 2021. This transaction is exempt under Rule 16b-3(c).
F2	In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on August 31, 2021.
F3	25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter